zidovudine

zidovudine is an antiretroviral medication used to prevent and treat HIV/AIDS, a disease caused by the Human Immunodeficiency Virus (HIV) that attacks the immune system of humans, as described by Luc Montagnier and Françoise Barré-Sinoussi. It was first approved by the US Food and Drug Administration (FDA) in 1987, and has since been used in combination with other medications, such as lamivudine and efavirenz, to treat HIV infection, as recommended by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). The development of zidovudine was a significant milestone in the fight against HIV/AIDS, and it has been recognized as a crucial component of antiretroviral therapy (ART) by Anthony Fauci and other leading researchers in the field, including David Ho and Martin Markowitz.

Introduction

zidovudine was first synthesized in 1964 by Jerome Horwitz at the Michigan Cancer Foundation, now known as the Barbara Ann Karmanos Cancer Institute, and was initially intended as a treatment for cancer, as part of a research program funded by the National Cancer Institute (NCI). However, it was later found to have antiviral properties, and was tested as a treatment for HIV by researchers at the National Institutes of Health (NIH), including Samuel Broder and Robert Gallo. The medication was approved by the US Food and Drug Administration (FDA) in 1987, and has since been used to treat HIV infection, often in combination with other medications, such as didanosine and stavudine, as part of a treatment regimen recommended by the European AIDS Clinical Society (EACS) and the International AIDS Society (IAS). The use of zidovudine has been supported by research conducted at institutions such as the University of California, San Francisco (UCSF) and the Massachusetts General Hospital (MGH), and has been recognized as a key component of HIV treatment by organizations such as the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the Bill and Melinda Gates Foundation.

Chemistry

The chemical structure of zidovudine is similar to that of thymidine, a naturally occurring nucleoside found in DNA, as described by James Watson and Francis Crick. It is a white, crystalline powder that is soluble in water, and is often formulated as a tablet or capsule for oral administration, as manufactured by companies such as GlaxoSmithKline and Pfizer. The chemical name for zidovudine is 3'-azido-3'-deoxythymidine, and it has a molecular weight of 267.24 g/mol, as reported in the Chemical Abstracts Service (CAS) database. The medication is also known by its trade name, Retrovir, which is marketed by ViiV Healthcare, a joint venture between GlaxoSmithKline, Pfizer, and Shionogi.

Mechanism_of_action

zidovudine works by inhibiting the action of the HIV reverse transcriptase enzyme, which is necessary for the replication of the HIV virus, as described by Kary Mullis and Michael Houghton. It is a nucleoside analog, which means that it is similar in structure to the nucleosides found in DNA, but has a slightly different chemical composition, as reported in the Journal of Medicinal Chemistry. When zidovudine is incorporated into the viral DNA, it acts as a chain terminator, preventing the further replication of the virus, as demonstrated by researchers at the University of Oxford and the University of Cambridge. This mechanism of action is similar to that of other nucleoside analogs, such as stavudine and lamivudine, which are also used to treat HIV infection, as recommended by the Pan American Health Organization (PAHO) and the African Union.

Medical_uses

zidovudine is used to treat HIV infection, and is often prescribed in combination with other medications, such as efavirenz and tenofovir, as part of a treatment regimen recommended by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). It is also used to prevent mother-to-child transmission of HIV, as part of a program supported by the United Nations Children's Fund (UNICEF) and the Elizabeth Glaser Pediatric AIDS Foundation. The medication has been shown to be effective in reducing the risk of HIV transmission from mother to child, as demonstrated by research conducted at institutions such as the Harvard School of Public Health and the London School of Hygiene and Tropical Medicine. Zidovudine has also been used to treat HIV-related illnesses, such as AIDS dementia complex, which is a condition characterized by cognitive impairment and neurological symptoms, as described by Luc Montagnier and Françoise Barré-Sinoussi.

Side_effects

The most common side effects of zidovudine include nausea, vomiting, and headache, as reported in the MedlinePlus database. The medication can also cause more serious side effects, such as anemia and neutropenia, which are conditions characterized by a decrease in the number of red and white blood cells, as described by researchers at the National Institutes of Health (NIH). In rare cases, zidovudine can cause lactic acidosis, a condition characterized by a buildup of lactic acid in the blood, as reported in the New England Journal of Medicine. The medication can also cause lipodystrophy, a condition characterized by changes in body fat distribution, as described by researchers at the University of California, Los Angeles (UCLA) and the University of Pennsylvania.

History

The development of zidovudine was a significant milestone in the fight against HIV/AIDS, and it has been recognized as a crucial component of antiretroviral therapy (ART) by Anthony Fauci and other leading researchers in the field, including David Ho and Martin Markowitz. The medication was first approved by the US Food and Drug Administration (FDA) in 1987, and has since been used to treat HIV infection, often in combination with other medications, such as didanosine and stavudine. The use of zidovudine has been supported by research conducted at institutions such as the University of California, San Francisco (UCSF) and the Massachusetts General Hospital (MGH), and has been recognized as a key component of HIV treatment by organizations such as the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the Bill and Melinda Gates Foundation. The development of zidovudine was also supported by the National Institutes of Health (NIH), the Wellcome Trust, and the Medical Research Council (MRC), among other organizations. Category:Antiretroviral drugs